Tyra Biosciences Inc

NASDAQ:TYRAUnited States

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Contact Information

Headquarters

2656 State StreetCARLSBAD, CA, United States 92008

Phone

619-728-4760

Fax

302-655-5049

Executives

Non-Executive Chairman of the Board

Robert More

President, Chief Executive Officer, Treasurer, Director

Todd Harris

Chief Financial Officer

Alan Fuhrman

Chief Operating Officer

Daniel Bensen

Chief Medical Officer

Douglas Warner